Does buying cheaper always mean earning more?

A lower price is one line of the economics

Once a chain has its own warehouse, its position has changed. Demand is aggregated, volumes are visible in one place, and the chain can distribute goods onward by itself. The obvious question follows: if we are already big enough, why buy only from the distributor?

A manufacturer can offer a lower price. What usually comes with it is a larger minimum lot, a longer replenishment time, less flexibility, more days of stock and more capital tied up in goods.

Buying cheaper is not the same thing as earning more.

When a manufacturer starts seeing a chain as a direct customer

A single pharmacy is rarely interesting to a manufacturer as a major buyer. Even a chain can remain, in their eyes, a scattering of small outlets if every one of them orders separately and needs its own delivery.

A central warehouse changes the picture. The chain can now show aggregated demand across all pharmacies, one delivery point, a clear volume per product or category, the ability to distribute the goods itself, and the ability to execute a larger contract. To the manufacturer that is a single buyer, one that distributes to its own pharmacies itself.

But a direct contract is only interesting when the chain can take over part of the distributor’s function in a way that makes economic sense.

Two sources, two different economics

A distributor’s economics are not built on resale alone. They hold stock, finance part of the cycle, break large lots, assemble a range across many manufacturers, deliver in small quantities and absorb part of the fluctuation in demand and supply. So a higher distributor price does not mean the function creates no value — just as a lower manufacturer price does not mean a direct contract is automatically better.

Price shows the cost of a unit. Stock shows the cost of the right to that price.

Which margin is actually a good margin?

A high margin percentage says nothing on its own about the quality of a decision. One product can carry a moderate margin and turn quickly. Another can carry twice the percentage, require a large lot, and lie there for months. What matters is not only the margin on one sale, but how much capital is continuously tied up in stock in order to earn it.

Practical reference points from our founder’s work in pharmacy — his own guide, not a universal market standard:

• Below 100% — weak return on inventory capital
• 100–200% — average
• 200–300% — high
• Above 300% — strong inventory-capital economics

And one warning: a high GMROI is not a good result if it was achieved through chronic shortage. Always read it next to availability.

How many months of demand are in one compulsory lot?

A category manager looks at demand, price, margin, positioning and the product’s place in the category. A factory looks at the minimum economic production run, line changeovers, production frequency, manufacturing and quality-control lead times. These two views can be far apart.

A high-margin SKU can be a bad decision. You cannot negotiate against the physics of a factory — but you can decline the purchase when the factory’s constraints do not fit your chain’s economics.

What if the good price requires more than you need?

A manufacturer may offer a lower price at a larger volume. The chain has a few options: decline; buy the whole volume and carry the surplus; or, where the market, licences and regulation allow, use part of the goods inside the network and sell part to other participants.

On some European markets, cross-border movement of original medicines under the established rules can fall under parallel trade. A larger purchase volume can lower the price for your own retail and create additional wholesale margin on part of the goods. But that does not turn every large purchase into a good deal, and it does not by itself turn a chain into a wholesaler. You need a lawful resale channel, buyers, and the ability to manage the extra stock, working capital and risk — and for medicines, the requirements on handling, traceability, packaging and labelling are especially important.

Private label: more margin, more responsibility

At sufficient scale a chain can commission production under its own brand. The factory produces to an agreed specification; the chain controls the product’s place in the range, its price positioning, the volume, the brand and the route to its own pharmacies. In a number of categories that means higher gross margin, a differentiated product, more control over price architecture, and a brand asset of your own.

It does not create profit automatically. The choice of manufacturer, the quality requirements, the stability of the specification, the volume forecast, the risk of surplus and the reputational risk of your own name all move to the chain.

The larger the share of the chain’s economics you keep, the more responsibility you must be able to carry.

There is a subtler trap too. Trouble starts when the economics of one SKU become more important than what the customer needs. At the level of a single line the numbers can look better; at the level of the customer relationship the chain can lose more. The most profitable product can be a bad decision if it costs you the customer. Private label should strengthen the category and the choice, not force the customer to submit to the chain’s internal economics.

Moving up the chain is economics, not a discount

Direct purchasing and private label become strategic when their total value — margin, capital, service, resilience, access and control — justifies the risk and the complexity of the function you have taken on.

A big discount may already be a sign of negotiating leverage. Durable additional strength from a new function appears only when the chain performs that function competitively, at its full cost and risk.

And direct buying does not create the surplus problem by itself. Surplus arises whether you buy from a distributor or a manufacturer: demand shifts, a promotion ends, sales slow, the volume was too large, commercial terms nudged you into extra stock. What the warehouse and centralised supply give you is a different capability — to see stock not as hundreds of separate balances but as one network resource.

Seven questions before you sign a direct contract

• How do days of stock change when we move to the direct source?
• How much capital does the minimum lot require?
• How many months of demand does one compulsory production run cover?
• What gross-margin return does the average stock create, per source?
• What risk of surplus and expiry are we taking on?
• Which of the distributor’s functions can we genuinely perform better ourselves?
• Are we increasing private-label margin at the cost of the customer’s choice and trust?

Related: Why adding a warehouse can cut stock · How to reduce overstock · Expiration and obsolete stock

The thinking in this article draws on The Evolution of the Pharmaceutical Market, a book by our founder Serzas Gutsaga.